EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Crizotinib resistance reversal in ALK-positive lung cancer through zeolitic imidazolate framework-based mitochondrial damage

Zhouhua Li, Xuehua Ma, Yanqiang Yang, Yanan Wang, Weihao Zhu, Xiaoxia Deng, Tianxiang Chen, Changyong Gao, Yongchang Zhang, Weichang Yang, Hongquan Xing, Xiaoqun Ye und 2 weitere

Acta Biomaterialia · 2024-09 · 185 · 381-395

DOI: 10.1016/j.actbio.2024.07.033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2024-09. Verfasst von Zhouhua Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Diseases, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China. Hauptthemen laut MEDLINE: Mitochondria, Lung Neoplasms, Drug Resistance, Neoplasm, Crizotinib. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jiangxi Provincial Department of Science and Technology, Nanchang University, Key Laboratory of Polysaccharide Bioactivity Evaluation of Traditional Chinese Medicine of Liaoning Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Crizotinib (CRZ), one of anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs), has emerged as a frontline treatment for ALK-positive (ALK+) lung adenocarcinoma. However, the overexpression of P-glycoprotein (P-gp, a mitochondrial adenosine triphosphate (ATP)-dependent protein) in lung adenocarcinoma lesions causes multidrug resistance (MDR) and limits the efficacy of CRZ treatment. Herein, a mitochondria-targeting nanosystem, zeolitic imidazolate framework-90@indocyanine green (ZIF-90@ICG), was fabricated to intervene in mitochondria and overcome drug resistance. Due to the zinc ion (Zn2+) interference of ZIF-90 and the photodynamic therapy (PDT) of ICG, this nanosystem is well suited for damaging mitochondrial functions, thus downregulating the intracellular ATP level and inhibiting P-gp expression. In addition, systematic bioinformatics analysis revealed the upregulation of CD44 in CRZ-resistant cells. Therefore, hyaluronic acid (HA, a critical target ligand of CD44) was further modified on the surface of ZIF-90@ICG for active targeting. Overall, this ZIF-90@ICG nanosystem synergistically increased the intracellular accumulation of CRZ and reversed CRZ resistance to enhance its anticancer effect, which provides guidance for nanomedicine design to accurately target tumours and induce mitochondrial damage and represents a viable regimen for improving the prognosis of patients with ALK-TKIs resistance. STATEMENT OF SIGNIFICANCE: The original aim of our research was to combat multidrug resistance (MDR) in highly aggressive and lethal lymphoma kinase-positive (ALK+) lung adenocarcinoma. For this purpose, a cascade-targeted system was designed to overcome MDR, integrating lung adenocarcinoma-targeted hyaluronic acid (HA), mitochondrion-targeted zeolitic imidazolate framework-90 (ZIF-90), the clinically approved drug crizotinib (CRZ), and the fluorescence imaging agent/photosensitizer indocyanine green (ICG). Moreover, using a "two birds with one stone" strategy, ion interference and oxidative stress induced by ZIF-90 and photodynamic therapy (PDT), respectively, disrupt mitochondrial homeostasis, thus downregulating adenosine triphosphate (ATP) levels, inhibiting MDR-relevant P-glycoprotein (P-gp) expression and suppressing tumour metastasis. Overall, this research represents an attempt to implement the concept of MDR reversal and realize the trade-offs between MDR and therapeutic effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitochondriaLung NeoplasmsDrug Resistance, NeoplasmCrizotinibAnaplastic Lymphoma KinaseZeolitesImidazolesHumansAnimalsCell Line, TumorMetal-Organic FrameworksMiceMice, NudePhotochemotherapy

Stichwörter der Autor:innen

Crizotinib resistanceHyaluronic acidMitochondrial damageP-glycoproteinZeolitic imidazolate framework

Substanzen

CrizotinibAnaplastic Lymphoma KinaseZeolitesImidazolesMetal-Organic FrameworksALK protein, human

Autor:innen und Institutionen

  • Department of Respiratory Diseases, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
  • Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Laboratory of Advanced Theranostic Materials and Technology, Chinese Academy of Sciences (CAS) Key Laboratory of Magnetic Materials and Devices…
  • Department of Respiratory Diseases, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China; Jiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of N…
  • Cixi Biomedical Research Institute, Wenzhou Medical University, Zhejiang 315300, China.
  • The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.

Förderung

  • Jiangxi Provincial Department of Science and Technology
  • Nanchang University
  • Key Laboratory of Polysaccharide Bioactivity Evaluation of Traditional Chinese Medicine of Liaoning Province
  • Ningbo Institute of Materials Technology and Engineering CAS
  • National Natural Science Foundation of China
  • National Synchrotron Radiation Laboratory
  • Soft Science Foundation of Ningbo Municipality
  • JiangXi Province Human Resources and Social Security Department

Zitieren

APA

Li, Z., Ma, X., Yang, Y., Wang, Y., Zhu, W., Deng, X., Chen, T., Gao, C., Zhang, Y., Yang, W., Xing, H., Ye, X., Wu, A., & Zhang, X. (2024). Crizotinib resistance reversal in ALK-positive lung cancer through zeolitic imidazolate framework-based mitochondrial damage. Acta Biomaterialia, 185, 381-395. https://doi.org/10.1016/j.actbio.2024.07.033

Vancouver

Li Z, Ma X, Yang Y, Wang Y, Zhu W, Deng X, et al. Crizotinib resistance reversal in ALK-positive lung cancer through zeolitic imidazolate framework-based mitochondrial damage. Acta Biomaterialia. 2024;185:381-395. doi:10.1016/j.actbio.2024.07.033

BibTeX
@article{Li2024,
  author = {Li, Zhouhua and Ma, Xuehua and Yang, Yanqiang and Wang, Yanan and Zhu, Weihao and Deng, Xiaoxia and Chen, Tianxiang and Gao, Changyong and Zhang, Yongchang and Yang, Weichang and Xing, Hongquan and Ye, Xiaoqun and Wu, Aiguo and Zhang, Xinyi},
  title = {Crizotinib resistance reversal in ALK-positive lung cancer through zeolitic imidazolate framework-based mitochondrial damage},
  journal = {Acta Biomaterialia},
  year = {2024},
  volume = {185},
  pages = {381--395},
  doi = {10.1016/j.actbio.2024.07.033}
}
Kostenlos starten →